{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nguyen VP"],"funding":["NEI NIH HHS","National Eye Institute","International Retinal Research Foundation","Foundation for the National Institutes of Health","Alcon Research Institute"],"pagination":["e2410166"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11879252"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(9)"],"pubmed_abstract":["Sustained-release ocular drug delivery systems with minimal invasiveness are critical for managing eye diseases that cause blindness. An innovative platform is presented for painless and long-term sustained ocular drug delivery utilizing controllably biodegradable silicon nanoneedles (Si NNs) conjugated with bevacizumab (Bev) integrated into a tear-soluble subconjunctival patch. The biocompatible patch facilitates easy application in the subconjunctival area of the eye and rapid dissolution in less than one minute upon contact with the tear film in the sclera, eliminating the need for removal procedures. The Si NNs, fabricated with precise control over their degradation kinetics, enable sustained and controlled release of Bev into the ocular tissues. This platform offers enhanced patient c"],"journal":["Small (Weinheim an der Bergstrasse, Germany)"],"pubmed_title":["Long-Term Diabetic Retinopathy Treatment Using Silicon Nanoneedles."],"pmcid":["PMC11879252"],"funding_grant_id":["1R01EY034325","YMP: 1R01EY033000","CHL: R01EY033000","1K08EY027458","R01 EY034325","YMP: FFSGIA16002","K08 EY027458","P30 EY001765","R01 EY033000"],"pubmed_authors":["Paulus YM","Jeong J","Zhe J","Lee CH","Zheng M","Lee J","Nguyen VP","Wei Z"],"additional_accession":[]},"is_claimable":false,"name":"Long-Term Diabetic Retinopathy Treatment Using Silicon Nanoneedles.","description":"Sustained-release ocular drug delivery systems with minimal invasiveness are critical for managing eye diseases that cause blindness. An innovative platform is presented for painless and long-term sustained ocular drug delivery utilizing controllably biodegradable silicon nanoneedles (Si NNs) conjugated with bevacizumab (Bev) integrated into a tear-soluble subconjunctival patch. The biocompatible patch facilitates easy application in the subconjunctival area of the eye and rapid dissolution in less than one minute upon contact with the tear film in the sclera, eliminating the need for removal procedures. The Si NNs, fabricated with precise control over their degradation kinetics, enable sustained and controlled release of Bev into the ocular tissues. This platform offers enhanced patient c","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-07-16T23:29:10.871Z","creation":"2026-07-12T03:11:19.977Z"},"accession":"S-EPMC11879252","cross_references":{"pubmed":["39910900"],"doi":["10.1002/smll.202410166"]}}